View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 15, 2021updated 12 Jul 2022 11:20am

Bioclinica unveils new solution for clinical trial management

Bioclinica has unveiled the new Source Document Manager solution that combines advanced software with redaction and translation services to offer support to global research site and trial management teams.

Bioclinica has unveiled the new Source Document Manager solution that combines advanced software with redaction and translation services to offer support to global research site and trial management teams.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Using the new solution, clinical trial sponsors and contract research organisations will be able to collect, de-identify, translate, organise, and manage source documents with the help of a secure, Cloud-based application.

Generating notable efficiencies at research sites, Source Document Manager eases trial management across the globe in patient eligibility, routine electronic data capture, clinical adjudication, and source document verification areas.

Bioclinica chief innovation officer Dan Gebow said: “The Covid-19 pandemic pushed the industry into decentralised trials and remote trial monitoring, exacerbating challenges with legacy technology and increasing the risk of noncompliance with regulatory requirements.

“Our solution was designed specifically to simplify the entire process of managing source documents in this environment using a single, centralised location.”

The company’s latest solution supports online protected health information redaction at the site level, with verification by quality control experts’ team.

It can also translate source documents by integrating with an online translation service directly.

Bioclinica Source Document Manager is capable of designating source documents as required or optional for clear guidance and can translate the entire interface into the local language and support multiple languages across a trial.

Furthermore, by de-identifying source documents prior to upload, it ensures every document is both AI-inspected and visually reviewed to ensure completeness.

The solution also has advanced search capabilities and can track every click for a complete audit trail of complete changes made to source documents at the time of processing.

For the collection and review of source documents online, it can be used as a standalone data collection and storage module.

Additionally, the Source Document Manager can be integrated with an existing EDC system or other data tracking system to transfer redacted and quality-controlled source documents to their destination.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena